Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) EBITDA (2017 - 2025)

Selectis Health's EBITDA history spans 14 years, with the latest figure at -$395676.0 for Q4 2025.

  • Quarterly results put EBITDA at -$395676.0 for Q4 2025, down 118.64% from a year ago — trailing twelve months through Dec 2025 was -$474210.0 (down 167.92% YoY), and the annual figure for FY2025 was -$1.6 million, down 207.38%.
  • EBITDA for Q4 2025 was -$395676.0 at Selectis Health, down from $67739.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.1 million in Q4 2024 to a low of -$2.6 million in Q4 2023.
  • The 5-year median for EBITDA is -$180106.0 (2024), against an average of -$204514.4.
  • The sharpest move saw EBITDA skyrocketed 85648.96% in 2022, then plummeted 1665.41% in 2023.
  • Year by year, EBITDA stood at -$715292.0 in 2021, then plummeted by 38.18% to -$988381.0 in 2022, then tumbled by 159.27% to -$2.6 million in 2023, then skyrocketed by 182.84% to $2.1 million in 2024, then crashed by 118.64% to -$395676.0 in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$395676.0, $67739.0, and -$87547.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.